Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 236


Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.

Re-examining Acute Eligibility for Thrombolysis (TREAT) Task Force:, Levine SR, Khatri P, Broderick JP, Grotta JC, Kasner SE, Kim D, Meyer BC, Panagos P, Romano J, Scott P; NINDS rt-PA Stroke Trial Investigators.

Stroke. 2013 Sep;44(9):2500-5. doi: 10.1161/STROKEAHA.113.000878. Epub 2013 Jul 11. Review. Erratum in: Stroke. 2014 Mar;45(3):e52.


Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.


Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.

Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention.

Stroke. 2016 Feb;47(2):581-641. doi: 10.1161/STR.0000000000000086. Epub 2015 Dec 22. Review. Erratum in: Stroke. 2016 Nov;47(11):e262.


Role of tissue plasminogen activator in acute ischemic stroke.

Hatcher MA, Starr JA.

Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Review.


Rapidly improving stroke symptoms: a pilot, prospective study.

Balucani C, Bianchi R, Ramkishun C, Weedon J, Law S, Szarek M, Rojas-Soto D, Tariq S, Levine SR.

J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1211-6. doi: 10.1016/j.jstrokecerebrovasdis.2015.01.017. Epub 2015 Apr 11.


Thrombolysis 2004: the good, the bad, and the ugly.

Caplan LR.

Rev Neurol Dis. 2004 Winter;1(1):16-26. Review.


Expansion of Intravenous Tissue Plasminogen Activator Eligibility Beyond National Institute of Neurological Disorders and Stroke and European Cooperative Acute Stroke Study III Criteria.

Marchidann A, Balucani C, Levine SR.

Neurol Clin. 2015 May;33(2):381-400. doi: 10.1016/j.ncl.2015.01.004. Epub 2015 Feb 28. Review.


The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.

Kamel H, Patel N, Rao VA, Cullen SP, Faigeles BS, Smith WS, Flint AC.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1111-6. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.017. Epub 2012 Nov 2.


Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.

Balucani C, Levine SR, Khoury JC, Khatri P, Saver JL, Broderick JP.

J Stroke Cerebrovasc Dis. 2016 Apr;25(4):894-901. doi: 10.1016/j.jstrokecerebrovasdis.2015.10.028. Epub 2016 Jan 26.


The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.

Flint AC, Gupta R, Smith WS, Kamel H, Faigeles BS, Cullen SP, Rao VA, Bath PM, Wahlgren N, Ahmed N, Donnan GA; SITS International and VISTA-plus investigators.

Int J Stroke. 2014 Aug;9(6):705-10. doi: 10.1111/ijs.12335. Epub 2014 Jul 15.


Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.

Chapman SN, Mehndiratta P, Johansen MC, McMurry TL, Johnston KC, Southerland AM.

Vasc Health Risk Manag. 2014 Feb 24;10:75-87. doi: 10.2147/VHRM.S39213. eCollection 2014. Review.


Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).

Eissa A, Krass I, Bajorek BV.

J Clin Pharm Ther. 2012 Dec;37(6):620-9. doi: 10.1111/j.1365-2710.2012.01366.x. Epub 2012 Jun 19. Review.


Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams.

Scott PA, Frederiksen SM, Kalbfleisch JD, Xu Z, Meurer WJ, Caveney AF, Sandretto A, Holden AB, Haan MN, Hoeffner EG, Ansari SA, Lambert DP, Jaggi M, Barsan WG, Silbergleit R.

Acad Emerg Med. 2010 Oct;17(10):1062-71. doi: 10.1111/j.1553-2712.2010.00868.x.


Thrombolysis for acute ischaemic stroke.

Wardlaw JM, Zoppo G, Yamaguchi T, Berge E.

Cochrane Database Syst Rev. 2003;(3):CD000213. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD000213.


Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke.

Daou B, Deprince M, D'Ambrosio R, Tjoumakaris S, Rosenwasser RH, Ackerman DJ, Bell R, Tzeng DL, Ghobrial M, Fernandez A, Shah Q, Gzesh DJ, Murphy D, Castaldo JE, Mathiesen C, Pineda MC, Jabbour P.

Clin Neurol Neurosurg. 2015 Dec;139:264-8. doi: 10.1016/j.clineuro.2015.10.010. Epub 2015 Oct 21.


Graphic reanalysis of the two NINDS-tPA trials confirms substantial treatment benefit.

Saver JL, Gornbein J, Starkman S.

Stroke. 2010 Oct;41(10):2381-90. doi: 10.1161/STROKEAHA.110.583807. Epub 2010 Sep 9.


Intravenous fibrinolysis eligibility: a survey of stroke clinicians' practice patterns and review of the literature.

De Los Rios F, Kleindorfer DO, Guzik A, Ortega-Gutierrez S, Sangha N, Kumar G, Grotta JC, Lee JM, Meyer BC, Schwamm LH, Khatri P; SPOTRIAS Investigators.

J Stroke Cerebrovasc Dis. 2014 Sep;23(8):2130-2138. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.024. Epub 2014 Aug 10.


Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.

Weintraub MI.

Stroke. 2006 Jul;37(7):1917-22. Epub 2006 May 25. Review.

Supplemental Content

Support Center